Stay updated on Pembrolizumab in Lymphopenic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Lymphopenic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Lymphopenic Breast Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    A sitewide banner announces an NIH transition notice about using “Super Intelligence” in place of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-25T06:24:20.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 on the 403 Forbidden page, while the study record remains inaccessible.
    Difference
    0.2%
    Check dated 2026-10-18T04:49:31.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The footer revision label was updated from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T06:42:44.000Z thumbnail image
  4. Check
    38 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error instead of loading the study record, effectively blocking access to the trial details and navigation on the ClinicalTrials.gov page.
    Difference
    19%
    Check dated 2026-09-20T03:47:41.000Z thumbnail image
  5. Check
    59 days ago
    Change Detected
    Summary
    The study record now includes an NIH grant/contract funding line (2016), and the page revision tag has been updated to v3.6.6, replacing the previous v3.6.5.
    Difference
    0.1%
    Check dated 2026-08-29T23:44:37.000Z thumbnail image
  6. Check
    80 days ago
    Change Detected
    Summary
    The page's revision label changed from v3.6.4 to v3.6.5, signaling a minor update to the study record.
    Difference
    0.1%
    Check dated 2026-08-08T22:26:58.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Lymphopenic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Lymphopenic Breast Cancer Clinical Trial page.